Linear IgG Clearance and Baseline Antibody Pharmacokinetics

Why Start With a Linear Baseline?

A mechanistic model of antibody disposition needs a reference case: what concentration-time profile would be expected if antibody were removed at a constant fractional rate, independently of its concentration? This linear baseline is useful both for interpreting exposure and for identifying patterns that may require additional mechanisms. It is not a claim that every therapeutic antibody follows this model under every condition.

The model below represents antibody amount in one well-mixed apparent compartment. It describes the simplest intravenous case and makes its assumptions explicit. In particular, it treats nonspecific elimination as linear: at any instant, the amount cleared per unit time is proportional to the antibody concentration. It does not represent distribution among multiple compartments, target binding, or the cellular processes involved in IgG recycling.

Definition: In the one-compartment linear-clearance model, $A(t)$ is the amount of antibody in the modeled compartment, $C(t)=A(t)/V$ is its concentration, $V$ is the apparent distribution volume, and $CL$ is the constant clearance. The elimination rate is $CL\,C(t)$, so in the absence of input: $$ \frac{dA}{dt}=-CL\,C(t), \qquad C(t)=\frac{A(t)}{V}. $$ Here $A$ is measured in amount, $C$ in amount per volume, $V$ in volume, and $CL$ in volume per time.

Bolus Dosing: Exponential Decline

For an intravenous bolus dose $D$, assume the dose enters the modeled compartment instantaneously at time zero, so $A(0)=D$. Assume $V$ and $CL$ remain constant, the compartment is well mixed, and there is no ongoing input after the dose. Substituting $A=VC$ into the amount balance gives $V\,dC/dt=-CL\,C$. Define the first-order elimination rate constant $k=CL/V$, with units of inverse time. The resulting concentration profile is exponential:

\frac{dC}{dt}=-kC, \qquad C(t)=C_0 e^{-kt}, \qquad C_0=\frac{D}{V}, \qquad k=\frac{CL}{V}.

The half-life is the time for concentration to fall to one-half its current value under this model. Setting $C(t_{1/2})/C_0=1/2$ gives $e^{-kt_{1/2}}=1/2$, and therefore $t_{1/2}=\ln(2)/k$. This half-life is constant: every equal time interval reduces concentration by the same fraction, not by the same absolute amount.

Derivation: Separating variables in $dC/dt=-kC$ gives $dC/C=-k\,dt$. Integrating from $C_0$ at time zero to $C(t)$ at time $t$ yields $\ln(C(t)/C_0)=-kt$. Exponentiating gives $C(t)=C_0e^{-kt}$. Integrating the resulting concentration profile over all time also gives the intravenous bolus exposure: $$ AUC_{0-\infty}=\int_0^\infty C_0e^{-kt}\,dt =\frac{C_0}{k} =\frac{D/V}{CL/V} =\frac{D}{CL}. $$

The rate constant $k$ and the clearance $CL$ are related but are not interchangeable. The rate constant describes the fractional decline per unit time; clearance describes the volume of plasma or blood, as defined by the model, cleared of antibody per unit time. The apparent volume also matters: two antibodies with the same clearance can have different half-lives if their apparent volumes differ.

Worked Example: A Single Intravenous Antibody Dose

Suppose a hypothetical antibody is given as a 100 mg intravenous bolus. Let $V=5.00$ L and $CL=0.250$ L/day. Use the linear one-compartment model to calculate the initial concentration, the half-life, and the concentration after 14 days.

The initial concentration and rate constant are $$ C_0=\frac{D}{V}=\frac{100\ \text{mg}}{5.00\ \text{L}}=20.0\ \text{mg/L}, \qquad k=\frac{CL}{V}=\frac{0.250\ \text{L/day}}{5.00\ \text{L}}=0.0500\ \text{day}^{-1}. $$

Thus the half-life is $$ t_{1/2}=\frac{\ln(2)}{k} =\frac{0.6931}{0.0500\ \text{day}^{-1}} =13.9\ \text{days}. $$

At 14 days, the predicted concentration is $$ C(14)=20.0\ \text{mg/L}\times e^{-(0.0500\ \text{day}^{-1})(14\ \text{days})} =20.0\times e^{-0.700} =9.93\ \text{mg/L}. $$

The model predicts about 9.93 mg/L at day 14. This is a model-based prediction under constant linear clearance and the stated one-compartment assumptions, not evidence that a real antibody must follow this profile.

Constant-Rate Infusion

For an infusion at a constant rate $R_0$, the amount balance includes an input term. With the same one-compartment and linear-clearance assumptions, $dA/dt=R_0-CL\,C$, or $dC/dt=R_0/V-kC$. If the infusion starts at time zero from $C(0)=0$, the concentration rises toward a steady state. At steady state, input equals elimination, so $R_0=CL\,C_{ss}$.

C(t)=\frac{R_0}{CL}\left(1-e^{-kt}\right), \qquad C_{ss}=\frac{R_0}{CL}.

The approach to steady state is governed by the same $k$ as the bolus decline. After one half-life, the concentration has reached one-half of its steady-state value; after several half-lives, it is progressively closer to steady state. The steady-state concentration depends on infusion rate and clearance, but not directly on $V$. The volume affects how quickly that concentration is approached.

Worked Example: Infusion Toward Steady State

Consider a hypothetical antibody infused at $R_0=10.0$ mg/day into a patient represented by $V=4.00$ L and $CL=0.200$ L/day. Assume the infusion begins with no antibody in the modeled compartment and that clearance is constant and linear. Calculate the steady-state concentration and concentration at day 10.

The elimination rate constant is $k=CL/V=0.200/4.00=0.0500\ \text{day}^{-1}$. The steady-state concentration is $$ C_{ss}=\frac{R_0}{CL} =\frac{10.0\ \text{mg/day}}{0.200\ \text{L/day}} =50.0\ \text{mg/L}. $$

At day 10, $$ C(10)=50.0\ \text{mg/L}\left(1-e^{-(0.0500\ \text{day}^{-1})(10\ \text{days})}\right) =50.0(1-e^{-0.500}) =19.7\ \text{mg/L}. $$

The predicted concentration is 19.7 mg/L, below the 50.0 mg/L steady state because the infusion has been running for less than one half-life of 13.9 days. The calculation assumes constant infusion and constant clearance throughout the interval.

Repeated Bolus Doses and Superposition

A useful consequence of linearity is superposition: the concentration from several doses is the sum of the concentrations each dose would produce on its own. For repeated intravenous boluses of dose $D$ at interval $\tau$, define $C_{\text{dose}}=D/V$ as the concentration increment caused by one dose. At periodic steady state, the peak immediately after a dose includes the current increment plus residual contributions from all earlier doses. The trough just before the next dose is the peak multiplied by $e^{-k\tau}$.

C_{\max,ss}=\frac{D/V}{1-e^{-k\tau}}, \qquad C_{\min,ss}=C_{\max,ss}e^{-k\tau}.

These expressions assume identical doses at a fixed interval, instantaneous intravenous input, constant $V$ and $CL$, and enough repeated dosing for the periodic steady-state pattern to be reached. They do not include an absorption phase or a target-mediated process.

Worked Example: Repeated Dosing at a Fixed Interval

Suppose a hypothetical antibody is administered as 200 mg intravenous boluses every 28 days. Let $V=5.00$ L and $CL=0.250$ L/day. Calculate the steady-state peak and trough concentrations using the linear model.

Here $D/V=200/5.00=40.0$ mg/L, $k=0.250/5.00=0.0500\ \text{day}^{-1}$, and $$ e^{-k\tau}=e^{-(0.0500\ \text{day}^{-1})(28\ \text{days})} =e^{-1.40}=0.2466. $$

The steady-state peak is $$ C_{\max,ss}=\frac{40.0\ \text{mg/L}}{1-0.2466} =53.1\ \text{mg/L}. $$

The trough is $$ C_{\min,ss}=53.1\ \text{mg/L}\times 0.2466 =13.1\ \text{mg/L}. $$

Under the stated assumptions, the predicted periodic steady-state concentrations range from approximately 13.1 mg/L just before a dose to 53.1 mg/L immediately after it. This calculation uses the residual concentration from prior doses; it does not assume that each dose starts from zero concentration.

What Changes With Target-Mediated Disposition?

The linear baseline removes antibody at a rate proportional to concentration, so the fractional elimination rate $k$ is constant. Target-mediated disposition (TMDD) is a different possibility: antibody can bind a finite amount of target, and the fate of the antibody may depend on what happens to the antibody–target complex. Because target binding and complex processing can contribute to antibody loss, the resulting fractional decline need not be constant as antibody concentration changes.

This distinction matters for dose predictions. Under the linear model, doubling an intravenous bolus dose doubles the concentration at every subsequent time, and $AUC_{0-\infty}=D/CL$ implies dose-proportional exposure when clearance is unchanged. If target-mediated removal contributes materially, the concentration-time profile may not scale this way across doses. In some settings, fractional removal is greater at low concentrations, so a low-dose profile can decline more rapidly in relative terms than a high-dose profile. The direction and size of such differences depend on the biology and cannot be inferred from the baseline model alone.

Feature	Linear baseline	Possible TMDD contribution
Rate of antibody removal	Proportional to concentration, with constant $CL$	May depend on target binding and complex fate
Fractional decline in a one-compartment profile	Constant $k=CL/V$	May change with concentration or time
Dose scaling	Proportional under unchanged parameters	May be nonproportional across doses
Interpretation of a single apparent half-life	Constant within the model	May not summarize the full profile

A curved semilog concentration-time plot, dose-dependent exposure, or different apparent slopes across dose levels can be reasons to examine alternatives to constant linear clearance. They do not, by themselves, prove TMDD: distribution between compartments, changing physiology, time-varying clearance, assay behavior, or other model misspecification can also produce departures from a single exponential decline. Compare profiles across doses and assess whether the departures are systematic before assigning a mechanism.

A multi-compartment linear model is one alternative when the dominant issue is distribution between spaces: it can produce more than one exponential phase while retaining linear clearance. A time-varying parameter model may be appropriate when physiology or treatment changes over time. A target-mediated model is relevant when there is independent mechanistic reason to represent target binding and the subsequent fate of bound antibody. These alternatives address different explanations; a visually better fit alone does not establish which mechanism is correct.

Assumptions, Diagnostics, and Limits

The baseline model is deliberately restrictive. Before using its equations, check that the intended application is consistent with its assumptions:

One well-mixed compartment: a single concentration represents the modeled antibody amount. If distribution phases are evident, this approximation may be inadequate.
Constant linear clearance: the amount eliminated per time is $CL\,C$, with the same $CL$ across the concentrations and times being considered.
Constant apparent volume: the relation $A=VC$ uses a fixed $V$.
Specified input: a bolus is treated as instantaneous, while an infusion is assumed to occur at its stated constant rate.
No explicit target or complex states: the model does not distinguish free antibody, bound antibody, or antibody in a complex.

Useful checks include plotting concentration against time on both ordinary and logarithmic scales, comparing observed and predicted profiles, and examining whether dose-normalized profiles approximately overlap. For a single exponential decline, the logarithm of concentration changes linearly with time, because $\ln C(t)=\ln C_0-kt$. Systematic curvature or dose-dependent slopes are warnings that the baseline assumptions may fail; they are not a diagnosis of the cause.

A common mistake is to call $CL/V$ the clearance. The units expose the error: $CL$ has units of volume per time, whereas $CL/V$ has units of inverse time and is the rate constant $k$. Another mistake is to interpret a fitted linear $CL$ as proof that antibody elimination is biologically nonspecific. It is a parameter of the chosen model; mechanistic interpretation requires evidence beyond a fit to one concentration-time profile.

Finally, the one-compartment model is a baseline, not a universal description of IgG pharmacokinetics. It is useful for transparent calculations, for defining dose-proportional reference behavior, and for recognizing when additional structure may be needed. Its predictions should not be extrapolated across dose ranges or physiological settings where constant linear clearance has not been justified.

Check Your Understanding

Answer each question, then compare with the solutions shown.

A hypothetical IV bolus gives $C_0=30.0$ mg/L and $k=0.0400\ \text{day}^{-1}$. What concentration does the linear model predict after 10.0 days? Solution: $C(10)=30.0e^{-(0.0400)(10.0)}=30.0e^{-0.400}=20.1$ mg/L.
If $CL=0.300$ L/day and $V=6.00$ L, calculate $k$ and the half-life. Solution: $k=CL/V=0.300/6.00=0.0500\ \text{day}^{-1}$, and $t_{1/2}=0.6931/0.0500=13.9$ days.
An infusion rate is 12.0 mg/day and clearance is 0.300 L/day. What is the predicted steady-state concentration under linear clearance? Solution: $C_{ss}=R_0/CL=12.0/0.300=40.0$ mg/L.
Why does a curved log-concentration-versus-time profile not establish TMDD? Solution: It indicates that a single exponential profile may be inadequate, but distribution between compartments, time-varying clearance, assay effects, or other misspecification can also cause curvature. Additional evidence is needed to attribute it to target-mediated disposition.
Under unchanged linear model parameters, what happens to the concentration profile and AUC if an IV bolus dose is doubled? Solution: The profile is multiplied by two because $C(t)=(D/V)e^{-kt}$, and $AUC_{0-\infty}=D/CL$ also doubles. This proportionality is a prediction of the model, not a guarantee for a system with concentration-dependent disposition.